You are here

BioVaxys Technology Corp.

Listing Exchange: 
CSE
Status: 
Active
Industry: 
Life Sciences
Symbol: 
BIOV
CSE Index: 
Currency: 

BioVaxys Technology Corp. is a British Columbia-registered biopharmaceuticals company based in Ontario, Canada that is developing BVX-0918, a personalized immunotherapeutic vaccine using our proprietary HapTenix© 'neoantigen' tumor cell construct platform for treating refractive late stage ovarian cancer. BioVaxys is also exploring vaccines for additional cancers and infectious diseases based on its HapTenix©platform through academic and other collaborations.

Home › Listings › Life Sciences › BioVaxys Technology Corp.

BioVaxys Technology Corp. (BIOV)

(%)

*Financial charts powered by Quotemedia.com. All right reserved. View the Terms of Use. Data delayed 15 minutes unless indicated.

Company Info

Address
146 Thirtieth Street
Suite 100
Etobicoke, ON M8W 3C4
Canada
Phone
646-452-7000
Email
jpassin@biovaxys.com
Website
https://biovaxys.com/
Listing date
Wednesday, November 21, 2018
Transfer Agent
Odyssey Trust Company
Email
news@biovaxys.com
Auditor
Dale Matheson Carr-Hilton Labonte LLP

SEDAR Information

Filing Type Any
Timeframe 1 week1 month3 month6 month1 yearAll Time

Search form

Company Info

Address
146 Thirtieth Street
Suite 100
Etobicoke, ON M8W 3C4
Canada
Phone
646-452-7000
Email
jpassin@biovaxys.com
Website
https://biovaxys.com/
Listing date
Wednesday, November 21, 2018
Transfer Agent
Odyssey Trust Company
Email
news@biovaxys.com
Auditor
Dale Matheson Carr-Hilton Labonte LLP

Capitalization

Issued & Outstanding: 
291525203
Reserved for Issuance: 
139701394

Company Officers

James Passin, CEO
Kenneth Kovan, COO & President
Christopher Cherry, Chief Financial Officer
James Passin, Chief Executive Officer
Christopher Cherry, Chief Financial Officer
Kenneth Kovan, Chief Operating Officer and President

News Releases

18/03/2025

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

03/03/2025

BioVaxys Technology Corp. Granted Management Cease Trade Order

Bulletins

16/07/2024

2024-0715 - Reinstatement - BioVaxys Technology Corp. (BIOV)

le 16 juillet/July 2024

Effective immediately, BioVaxys Technology Corp. will be reinstated for trading.

The Company has rectified the situation that gave rise to the suspension.

____________________________

Avec effet immédiat, BioVaxys Technology Corp. sera réintégrée à la négociation.

La Société a rectifié la situation qui a donné lieu à la suspension.

CSE Filings

BioVaxys Technology Corp. - CSE Form 5 - Quarterly Listing Statement

BioVaxys Technology Corp. - CSE Form 5A - Annual Listing Summary

BioVaxys Technology Corp. - CSE Form 7 - Monthly Progress Report for February 2025

BioVaxys Technology Corp. - CSE Form 6 - Certificate of Compliance

BioVaxys Technology Corp. - CSE Form 9 - Notice of Issuance or Proposed Issuance of Listed Securities